

REFERENCES

1. Izaks GJ, Westendorp RG, Knook DL. The definition of anemia in older persons. *JAMA*. 1999;281:1714-1717.
2. Salive ME, Cornoni-Huntley J, Guralnik JM, et al. Anemia and hemoglobin levels in older persons: relationship with age, gender, and health status. *J Am Geriatr Soc*. 1992;40:489-496.
3. Carson JL, Poses RM, Spence RK, Bonavita G. Severity of anaemia and operative mortality and morbidity. *Lancet*. 1988;1:727-729.
4. Jazieh AR, Hussain M, Howington JA, et al. Prognostic factors in patients with surgically resected stages I and II non-small cell lung cancer. *Ann Thorac Surg*. 2000;70:1168-1161.
5. Dunne JR, Malone D, Tracy JK, et al. Perioperative anemia: an independent risk factor for infection, mortality, and resource utilization in surgery. *J Surg Res*. 2002;102:237-244.
6. Aldemir M, Ozen S, Kara IH, et al. Predisposing factors for delirium in the surgical intensive care unit. *Crit Care*. 2001;5:265-270.
7. Halm EA, Wang JJ, Boockvar K, et al. The effect of perioperative anemia on clinical and functional outcomes in patients with hip fracture. *J Ortho Trauma*. 2004;18:369-374.
8. Pfeifer K, Carson JL. Anemia and bleeding. In: Cohn SL, Smetana G, Weed HG. *Perioperative Medicine: Just the Facts*. 1st ed. New York, NY: McGraw-Hill; 2006:320-326.
9. Hoffman R, Furie B, Benz EJ, et al. *Hematology: Basic Principles and Practice, Expert Consult Premium Edition*. 5th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2009.
10. IV. NKF-K/DOQI Clinical Practice Guidelines for anemia of chronic kidney disease: update 2000. *Am J Kidney Dis*. 2001;37(suppl 1):S182-S238. [Erratum in: *Am J Kidney Dis*. 2001;38:442.]
11. Janik J, Seeler AS. Perioperative management in children with sickle hemoglobinopathy. *Pediatr Surg*. 1980;15:117-120.
12. Rutledge R, Croom RD 3rd, Davis JW Jr, et al. Cholelithiasis in sickle cell anemia: surgical considerations. *South Med J*. 1986;79:28-30.
13. Gibson JR. Anesthesia for sickle cell diseases and other hemoglobinopathies. *Sem Anesthesia*. 1987;4:27-35.
14. Ware R, Filston HC, Schultz WH, Kinney TR. Elective cholecystectomy in children with sickle hemoglobinopathies. Successful outcome using a preoperative transfusion regimen. *Ann Surg*. 1988;208:17-22.
15. Esseltine DW, Baxter MR, Bevan JC. Sickle cell states and the anaesthetist. *Can J Anaesth*. 1988;35:385-403.
16. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. *N Engl J Med*. 1995;333:206-212.
17. Koshy M, Weiner SJ, Miller ST, et al. Surgery and anesthesia in sickle cell disease. Cooperative Study of Sickle Cell Disease. *Blood*. 1995;66:3676-3684.
18. Hirst C, Williamson L. Preoperative blood transfusions for sickle cell disease (review). The Cochrane Library. 2010;2:CD003149. Available at: <http://www.thecochranelibrary.com/SpringboardWebApp/userfiles/ccoch/file/CD003149.pdf>. April 20, 2010.
19. Al-Jaouni S, Al-Muhayawi SM, Qari MH, et al. Randomized clinical trial to evaluate the safety of avoiding pre-operative transfusion in sickle cell anemia. *Bahrain Medical Bulletin*. 2006;28:164-167.
20. The Management of Sickle Cell Disease. 4th ed. Bethesda, MD: National Institutes of Health. National Heart, Lung, and Blood Institute. NIH Publication No. 02-2117; June 2002. Available at: http://www.nhlbi.nih.gov/health/prof/blood/sickle/sc_mngt.pdf. Accessed April 20, 2010.
21. Rogers MAM, Blumberg N, Saint S, et al. Hospital variation in transfusion and infection after cardiac surgery: a cohort study. *BMC Med*. 2009;7:37.
22. Shiba H, H, Ishida Y, Wakiyama S, et al. Negative impact of blood transfusion on recurrence and prognosis of hepatocellular carcinoma after hepatic resection. *J Gastrointest Surg*. 2009;13:1336-1342.
23. Maluenda G, G, Lemesle G, Ben-Dor I, et al. Value of blood transfusion in patients with blood hematocrit level of 24% to 30% after percutaneous coronary intervention. *Am J Cardiol*. 2009;104:1069-1073.
24. Carson JL, Duff A, Berlin JA, et al. Influence of perioperative blood transfusion on postoperative mortality. *JAMA*. 1998;279:199-205.
25. Hebert PC, Wells G, Blajchman MA, et al. A multicenter randomized controlled clinical trial of transfusion requirements in critical care. *N Engl J Med*. 1999;340:409-417.
26. American Heart Association. Study finds no significant cardiovascular differences between more aggressive or restrictive post-operative treatment of anemia [news release]. Available at: <http://americanheart.mediaroom.com/index.php?s=43&item=886>. Accessed April 20, 2010.
27. Krantz SB. Pathogenesis and treatment of the anemia of chronic disease. *Am J Med Sci*. 1994;307:353-359.
28. Bezwada HP, Nazarian DG, Henry DH, Booth RE Jr. Preoperative use of recombinant human erythropoietin before total joint arthroplasty. *J Bone Joint Surg Am*. 2003;85-A(9):1795-1800.
29. Feagan BG, Wong CJ, Kirkley A, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. *Ann Intern Med*. 2000;133:845-854.
30. Goldberg MA, McCutchen JW, Jove M, et al. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. *Am J Orthop*. 1996;25:544-552.
31. Heiss MM, Tarabichi A, Delanoff C, et al. Perisurgical erythropoietin application in anemic patients with colorectal cancer: a double-blind randomized study. *Surgery*. 1996;119:523-527.
32. Weber EW, Slappendel R, Hémon Y, et al. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST). *Eur J Anaesthesiol* 2005;22:249-257.
33. Information for healthcare professionals: erythropoiesis stimulating agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]. US Food and Drug Administration Web site. Available at: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126481.htm>. Accessed April 20, 2010.
34. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. *N Engl J Med*. 2006;355:2085-2098.
35. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. *JAMA*. 2008;299:914-924.
36. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. *N Engl J Med*. 2006;355:2071-2084.
37. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. *N Engl J Med*. 2007;357:965-976.
38. Careless, PA, Henry DA, Moxey AJ, et al. Cell salvage for minimizing perioperative allogeneic blood transfusion. *Cochrane Database Syst Rev*. 2006;(4):CD001888.
39. Goodnough LT. Autologous blood donation. *Crit Care*. 2004;8:S49-S52.
40. Jacob M, Bruegger D, Conzen P, et al. Development and validation of a mathematical algorithm for quantifying preoperative blood volume by means of the decrease in hematocrit resulting from acute normovolemic hemodilution. *Transfusion*. 2005;45:562-571.

41. Segal JB, Blasco-Colmenares E, Norris EJ, Guallar E. Preoperative acute normovolemic hemodilution: a meta-analysis. *Transfusion*. 2004;44:632-644.
42. Jarnagin VR, Gonen M, Maitzel SK, et al. A prospective randomized trial of acute normovolemic hemodilution compared to standard intraoperative management in patients undergoing major hepatic resection. *Ann Surg*. 2008;248:360-369.